Related references
Note: Only part of the references are listed.Comparison of Anti-Xa Levels in Obese and Non-Obese Pediatric Patients Receiving Treatment Doses of Enoxaparin
Ashley A. Richard et al.
JOURNAL OF PEDIATRICS (2013)
Parenteral Anticoagulants Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
David A. Garcia et al.
CHEST (2012)
Executive Summary Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Gordon H. Guyatt et al.
CHEST (2012)
Anticoagulation therapy for hospitalized patients: Patterns of use, compliance with national guidelines, and performance on quality measures
Funda Tiryaki et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2011)
Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series
Eli N. Deal et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2011)
Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international survey
Michael A. Barras et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Obesity in patients with non-ST-segment elevation acute coronary syndromes: Results from the SYNERGY trial
Kenneth W. Mahaffey et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2010)
Prevalence and Trends in Obesity Among US Adults, 1999-2008
Katherine M. Flegal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
Human Organ/Tissue Growth Algorithms that Include Obese Individuals and Black/White Population Organ Weight Similarities from Autopsy Data
John F. Young et al.
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES (2009)
Weight-Based Dosing of Enoxaparin in Obese Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: Results from the CRUSADE Initiative
Sarah A. Spinler et al.
PHARMACOTHERAPY (2009)
Obesity and Incremental Hospital Charges among Patients with and without Diabetes in the United States
Sunny Kim et al.
VALUE IN HEALTH (2009)
The influence of extreme body weight on clinical outcome of patients with venous thromboembolism:: findings from a prospective registry (RIETE)
R Barba et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes
B Green et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Quantification of lean bodyweight
S Janmahasatian et al.
CLINICAL PHARMACOKINETICS (2005)
Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies
SA Spinler et al.
AMERICAN HEART JOURNAL (2003)
Development of a dosing strategy for enoxaparin in obese patients
B Green et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers
GJ Sanderink et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
Share Paper
